Wall Street hikes forecasts for anti-obesity drug sales to $100 billion and beyond — A look at the numbers
Citi notched its estimate for incretin drug sales to $71 billion by 2035, up from its prior estimate of $55 billion. That view seems conservative.
Eli Lilly Is Waiting for Obesity-Drug Approval. Here's How Much It Could Be Worth.
Eli Lilly's diabetes drug Mounjaro is expected to be approved to treat obesity in the near future. It could drive sales for more than a decade.
Eli Lilly, Novo Nordisk to test weight loss drugs for children
Pharmaceutical manufacturers Eli Lilly (LLY) and Novo Nordisk (NVO) are reportedly planning to test their weight loss drugs for children six and older. Yahoo Finance Health Reporter Anjalee Khemlan...
Pharma firms testing weight loss drugs for kids amid Ozempic craze
Get ready for Ozem-kids! The pharmaceutical companies behind Ozempic, Mounjaro and Wegovy — which have exploded in popularity with adults looking to lose weight — are testing whether the drugs are ...
Drugmakers test weigh-loss shots for kids as young as 6
Former FDA commissioner Dr. Scott Gottlieb joins 'Power Lunch' to discuss the latest weight loss headlines.
Eli Lilly planning diabetes drug trial for children six years and older: report
Eli Lilly and Co (NYSE:LLY) is planning a trial of its diabetes drug Mounjaro in patients with obesity as young as six years old according to a Bloomberg report Friday citing a person familiar with...
Eli Lilly plans diabetes drug trial for kids as young as 6 years - Bloomberg
Eli Lilly is planning a clinical trial of its diabetes drug Mounjaro in patients six years and older who have obesity, Bloomberg News reported on Friday, citing a person familiar with the matter.
Hundreds of online sellers are offering an Eli Lilly weight-loss drug that's years away from regulatory approval: WSJ
Hundreds of online sellers are offering Eli Lilly' & Co.'s LLY, -2.71% retatrutide weight-loss drug for sale, even though the drug is years away from gaining regulatory approval, the Wall Street Jo...
Eli Lilly sues online pharmacies to ban US imports of fake Mounjaro
Eli Lilly on Thursday said it sued 11 online pharmacies to stop them from importing, selling and distributing products claiming to contain the active ingredient in its diabetes drug Mounjaro, which...
Exclusive: Lilly hires CordenPharma to make diabetes drug Mounjaro's active ingredient -source
Eli Lilly has hired Switzerland-based contract drugmaker CordenPharma to produce the active ingredient in its diabetes drug Mounjaro, a source familiar with the matter told Reuters on Thursday.
4 Ways to Grow $100,000 Into $1 Million for Retirement
Realty Income's total returns deliver. Alphabet is still turning investors into millionaires.
The Next Trillion-Dollar Companies: 3 Stocks to Buy Now
The hunt for the next trillion-dollar companies invariably ignites investor excitement. Moreover, the AI-led excitement in equities this year pushed tech stocks to new highs while others reversed t...
Eli Lilly is buying another European cancer firm Mablink Bioscience
Eli Lilly & Co (NYSE: LLY) is buying Mablink Bioscience – a French biotechnology company that focuses primarily on the next-generation, antibody-drug conjugates for cancer. It's the 2nd cancer comp...
Eli Lilly (LLY) Registers a Bigger Fall Than the Market: Important Facts to Note
Eli Lilly (LLY) reachead $608.31 at the closing of the latest trading day, reflecting a -1.35% change compared to its last close.
Ozempic Sales Are Skyrocketing Faster Than Expected. Here's Why That's Great News for Eli Lilly Stock.
Novo Nordisk recently raised its full-year 2023 guidance in large part because of greater sales expectations for Ozempic. The same dynamics behind Ozempic's success are also helping Lilly's Mounjaro.
Related Companies